WO2020141825A1 - 정제 및 이의 제조방법 - Google Patents
정제 및 이의 제조방법 Download PDFInfo
- Publication number
- WO2020141825A1 WO2020141825A1 PCT/KR2019/018684 KR2019018684W WO2020141825A1 WO 2020141825 A1 WO2020141825 A1 WO 2020141825A1 KR 2019018684 W KR2019018684 W KR 2019018684W WO 2020141825 A1 WO2020141825 A1 WO 2020141825A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tablet
- granules
- layer
- atorvastatin
- pharmaceutically acceptable
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 51
- 239000008187 granular material Substances 0.000 claims abstract description 166
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims abstract description 98
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims abstract description 98
- 229960005370 atorvastatin Drugs 0.000 claims abstract description 98
- 229960003489 fimasartan Drugs 0.000 claims abstract description 97
- AMEROGPZOLAFBN-UHFFFAOYSA-N fimasartan Chemical compound CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 AMEROGPZOLAFBN-UHFFFAOYSA-N 0.000 claims abstract description 95
- 239000005475 Fimasartan Substances 0.000 claims abstract description 83
- 239000002245 particle Substances 0.000 claims abstract description 72
- 238000009826 distribution Methods 0.000 claims abstract description 45
- 239000010410 layer Substances 0.000 claims description 91
- 239000000203 mixture Substances 0.000 claims description 66
- 238000004519 manufacturing process Methods 0.000 claims description 54
- 150000003839 salts Chemical class 0.000 claims description 53
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 38
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 38
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 38
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 38
- 239000012453 solvate Substances 0.000 claims description 38
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 34
- 239000000654 additive Substances 0.000 claims description 29
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 28
- 230000000996 additive effect Effects 0.000 claims description 26
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 19
- 229940088417 precipitated calcium carbonate Drugs 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 17
- -1 dissolution aids Substances 0.000 claims description 16
- 206010020772 Hypertension Diseases 0.000 claims description 15
- 239000000314 lubricant Substances 0.000 claims description 15
- 239000011230 binding agent Substances 0.000 claims description 13
- 239000002552 dosage form Substances 0.000 claims description 12
- 239000007884 disintegrant Substances 0.000 claims description 11
- 238000004090 dissolution Methods 0.000 claims description 11
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 10
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 8
- 208000006011 Stroke Diseases 0.000 claims description 7
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 206010019280 Heart failures Diseases 0.000 claims description 6
- 208000029078 coronary artery disease Diseases 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 206010012289 Dementia Diseases 0.000 claims description 5
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 5
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 5
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 5
- 206010022489 Insulin Resistance Diseases 0.000 claims description 5
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 5
- 201000001068 Prinzmetal angina Diseases 0.000 claims description 5
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 5
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 5
- 208000007718 Stable Angina Diseases 0.000 claims description 4
- 239000011247 coating layer Substances 0.000 claims description 4
- 230000006999 cognitive decline Effects 0.000 claims description 4
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 2
- 208000001280 Prediabetic State Diseases 0.000 claims description 2
- 239000003826 tablet Substances 0.000 description 136
- 239000004480 active ingredient Substances 0.000 description 63
- 229960004829 atorvastatin calcium trihydrate Drugs 0.000 description 50
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 20
- 208000035475 disorder Diseases 0.000 description 17
- 238000002156 mixing Methods 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 239000011248 coating agent Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 238000000576 coating method Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 229920002785 Croscarmellose sodium Polymers 0.000 description 11
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 10
- 229960001681 croscarmellose sodium Drugs 0.000 description 10
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 10
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 10
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 10
- 235000019359 magnesium stearate Nutrition 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical class CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 8
- 229940068968 polysorbate 80 Drugs 0.000 description 8
- 229920000053 polysorbate 80 Polymers 0.000 description 8
- 150000004684 trihydrates Chemical class 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000004203 carnauba wax Substances 0.000 description 7
- 235000013869 carnauba wax Nutrition 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000007942 layered tablet Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 229960001770 atorvastatin calcium Drugs 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000011164 primary particle Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000011077 uniformity evaluation Methods 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 2
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- ODYFGDACHPDINU-UHFFFAOYSA-N O.O.O.[Ca] Chemical compound O.O.O.[Ca] ODYFGDACHPDINU-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940033134 talc Drugs 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229920006310 Asahi-Kasei Polymers 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- 0 CCCCC(*1Cc(cc2)ccc2-c(cccc2)c2C(*=*2)=*C*2I)=*C(C)=C(CC(*(C)C)=N)C1=O Chemical compound CCCCC(*1Cc(cc2)ccc2-c(cccc2)c2C(*=*2)=*C*2I)=*C(C)=C(CC(*(C)C)=N)C1=O 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- NEMAFRGLILBGGG-UHFFFAOYSA-N O.O.O.C(CCCCC(=O)O)(=O)O Chemical compound O.O.O.C(CCCCC(=O)O)(=O)O NEMAFRGLILBGGG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000364051 Pima Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 description 1
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000007561 laser diffraction method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- DVQHRBFGRZHMSR-UHFFFAOYSA-N sodium methyl 2,2-dimethyl-4,6-dioxo-5-(N-prop-2-enoxy-C-propylcarbonimidoyl)cyclohexane-1-carboxylate Chemical group [Na+].C=CCON=C(CCC)[C-]1C(=O)CC(C)(C)C(C(=O)OC)C1=O DVQHRBFGRZHMSR-UHFFFAOYSA-N 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000008054 sulfonate salts Chemical class 0.000 description 1
- TXKRWVMEUQBFSO-UHFFFAOYSA-N sulfuric acid;trihydrate Chemical compound O.O.O.OS(O)(=O)=O TXKRWVMEUQBFSO-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- CUGZEDSDRBMZMY-UHFFFAOYSA-N trihydrate;hydrochloride Chemical compound O.O.O.Cl CUGZEDSDRBMZMY-UHFFFAOYSA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to tablets and methods for their preparation.
- Hypertension is important to prevent coronary artery disease and cardiovascular complications such as life-threatening stroke, heart failure, and myocardial infarction by maintaining blood pressure in the normal range rather than treating blood pressure itself, so it is steadily lowering blood pressure below a certain pressure. It is important to adjust.
- Fimasartan represented by the following Chemical Formula 1 is known as an angiotensin II receptor antagonist developed to treat hypertension and other medical signs (Korean Patent No. 10-1058284).
- the fimasartan is 2-n-butyl-5-dimethylaminothiocarbonylmethyl-6-methyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]pyri Midine-4(3H)-one, a non-peptide molecule chemically described, empirical formula is C 27 H 30 N 7 OS, and molecular weight is 501.65.
- Fimasartan is marketed in Korea as an item license with fimasartan potassium trihydrate.
- atorvastatin represented by the following formula (2) is a selective and competitive HMG-CoA reductase inhibitor, atorvastatin calcium salt, which is a representative salt of atorvastatin (chemical name: [R-(R*,R*)]-2- (4-Fluorophenyl)- ⁇ , ⁇ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptate calcium salt (2:1)) is a lipid-lowering agent that lowers the concentration of low-density lipoprotein cholesterol and is useful in the treatment of hyperlipidemia.
- atorvastatin calcium is known to reduce mortality and stroke from cardiovascular-related diseases.
- Tablets containing fimasartan and atorvastatin with different mechanisms of action may be considered to more effectively treat cardiovascular disease, including hypertension, but tableting such as stirring of atorvastatin during this tableting process Disability occurs.
- Non-Patent Document 1 Compatibility study of Atorvastatin Calcium and Telmisartan with selected excipients and formulation of a bilayer tablet using box behnkein design, Bajracharya et. al., Am. J. PharmTech Res. 2015; 5(3) ISSN: 2249-3387
- the present invention relates to a tablet and a method of manufacturing the atorvastatin granules having a particle size distribution of a certain level or more so that the tableting process can be remarkably improved in a tableting process with fimasartan.
- the present invention is a fimasartan granule part containing fimasartan, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof and a pharmaceutically acceptable additive; And an atorvastatin granule part containing atorvastatin, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, and a pharmaceutically acceptable additive, wherein the fimasartan granule part and the atorvastatin granule part are present separately.
- the present invention is fimasartan, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof and a first layer comprising granules containing a pharmaceutically acceptable additive; And a second layer comprising granules containing atorvastatin, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, and a pharmaceutically acceptable additive, wherein the granule of the second layer has a D 50 of 80 ⁇ m or more.
- Provided are tablets that exhibit a particle size distribution.
- the present invention fimasartan, a pharmaceutically acceptable salt, a hydrate or solvate thereof and a first layer containing a granule containing a pharmaceutically acceptable additive; (S2) preparing a second layer containing granules comprising atorvastatin, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, and a pharmaceutically acceptable additive; And (S3) tableting the first layer and the second layer to produce a two-layer tablet.
- the present invention provides a pharmaceutical composition comprising the tablet.
- the present invention provides a method for preventing or treating cardiovascular disease, comprising administering to a mammal, including a human, in a therapeutically effective amount of the tablet.
- the present invention provides the use of such tablets for use in the manufacture of cardiovascular disease agents.
- the present invention provides the use of the tablets for the treatment of cardiovascular diseases.
- tablets containing fimasartan active ingredient and atorvastatin active ingredient were developed by solving the tableting disorder of atorvastatin in the process of tabletting with fimasartan by applying the particle size control technology of atorvastatin granules, and the tablets are particularly useful. It was confirmed that the mass variation of atorvastatin was within a suitable range, so that it could be produced according to a target weight, so that it could have excellent content uniformity.
- the present invention is a fimasartan granule part containing fimasartan, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof and a pharmaceutically acceptable additive; And an atorvastatin granule part containing atorvastatin, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, and a pharmaceutically acceptable additive, wherein the fimasartan granule part and the atorvastatin granule part are present separately.
- the present invention comprises a first layer comprising granules containing fimasartan, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof and a pharmaceutically acceptable additive; And a second layer comprising granules containing atorvastatin, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, and a pharmaceutically acceptable additive, wherein the granule of the second layer has a D 50 of 80 ⁇ m or more.
- a first layer comprising granules containing fimasartan, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof and a pharmaceutically acceptable additive
- a second layer comprising granules containing atorvastatin, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, and a pharmaceutically acceptable additive, wherein the granule of the second layer has a D 50 of 80 ⁇ m or more.
- Atorvastatin is very difficult to formulate when preparing a complex with fimasartan, and because of low stability of atorvastatin, a large amount of finely precipitated calcium carbonate is added as a stabilizing agent, thereby causing tabletting failure during tableting with fimasartan and bilayer tablets. This leads to cosmetic disorders that lack part of the formulation. In the case of manufacturing on a production scale, it is envisaged that such a tableting impediment causes the machine to stop, and the production itself becomes difficult. In addition, even when the identification code is imprinted on the tablet surface, omission of imprinting occurs due to a tableting problem, which is a major problem.
- the particle size distribution of the atorvastatin granules included in the second layer is adjusted to a value equal to or more than a predetermined value, so that it is possible to express ease of tableting in the purification process for preparing fimasartan and the complex agent. .
- the term "fimasartan” means 2-n-butyl-5-dimethylaminothiocarbonylmethyl-6-methyl-3-[[2'-(1H-tetrazol-) represented by the following formula (1) 5-yl)biphenyl-4-yl]methyl]pyrimidin-4(3H)-one, meaning angiotensin II receptor antagonist developed to treat hypertension and other medical signs.
- atorvastatin is a lipid-lowering agent that lowers the concentration of low-density lipoprotein cholesterol represented by the following formula (2), a selective and competitive HMG-CoA reductase inhibitor that is useful for the treatment of hyperlipidemia to be.
- the term "pharmacologically acceptable” refers to a physiologically acceptable, when administered to humans, that usually does not cause an allergic reaction such as gastrointestinal disorders, dizziness or similar reactions, and the term “salt” Iran means an acid addition salt formed by a pharmaceutically acceptable free acid.
- the pharmaceutically acceptable salt of the fimasartan may be selected from the group consisting of inorganic ionic salts, inorganic acid salts, organic acid salts, sulfonate salts, amino acid salts and amine salts.
- the pharmaceutically acceptable salt of fimasartan is an inorganic ionic salt made of calcium, potassium, sodium or magnesium, an inorganic acid salt made of hydrochloric acid, nitric acid, phosphoric acid, bromic acid, iodic acid, perchloric acid or sulfuric acid, Acetic acid, trifluoroacetic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, Organic acid salts, methanesulfonic acid, ethanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, made of ascorbic acid, carbonic acid, vanic acid, mandelic acid, mumic acid
- the pharmaceutically acceptable salt of atorvastatin is an inorganic ion salt made of calcium, strontium, sodium, potassium, magnesium, ammonium, hydrochloric acid, nitric acid, phosphoric acid, bromic acid, iodic acid, Inorganic acid salts made of perchloric acid or sulfuric acid, and the like, but the types of salts in the present invention are not limited by the salts listed.
- the pharmaceutically acceptable salt of atorvastatin may be atorvastatin calcium salt.
- the term "hydrate” means that the active ingredient and water are bound by the force between non-covalent molecules, and includes a stoichiometric or non-stoichiometric amount of water.
- the hydrate may include water in an amount of about 0.25 mol to about 10 mol based on 1 mol of the active ingredient, and more specifically, about 0.5 mol, about 1 mol, about 1.5 mol, about 2 mol, about 3 moles, about 5 moles, and the like.
- the fimasartan hydrate is fimasartan potassium trihydrate, fimasartan hydrochloride trihydrate, fimasartan calcium trihydrate, fimasartan sulfate trihydrate, fimasartan adipate trihydrate, fimasartan camsylate trihydrate It may be any one selected from the group consisting of cargo and fimasartan besylate trihydrate, but is not limited thereto, and may specifically be fimasartan potassium trihydrate.
- the hydrate of the fimasartan or a pharmaceutically acceptable salt thereof may be a monohydrate or a trihydrate, specifically a fimasartan potassium monohydrate or a trihydrate, and more specifically It may be a trihydrate of fimasartan potassium.
- the hydrate of the atorvastatin or a pharmaceutically acceptable salt thereof may be a trihydrate, specifically, a trihydrate of atorvastatin calcium, but is not limited thereto.
- solvate means that the active ingredient and the solvent are combined by the force between non-covalent molecules, and includes a stoichiometric or non-stoichiometric amount of a solvent.
- Preferred solvents are volatile, non-toxic, and can be administered in very small amounts to humans.
- solvates of the present invention are not limited by these examples, specifically, the solvate contains 1 mole of the active ingredient.
- water may be included in a ratio of about 0.25 mol to about 10 mol, and more specifically, may include about 0.5 mol, about 1 mol, about 1.5 mol, about 2 mol, about 3 mol, about 5 mol, and the like. .
- the term "about” means a 10% deviation from the labeled value (eg, 1 mol, 2 mol%, 3 mol%, etc.), or in the case of a numerical range, both the lower and upper limits of the range. Means 10% deviation from.
- “about 1 mole” refers to a range from 0.9 mole to 1.1 mole.
- the term “granules” means smaller primary particles or solid particles composed of primary particles.
- the term "fimasartan, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof and a granule containing a pharmaceutically acceptable additive” refers to fimasartan, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof and a pharmaceutical
- a primary particle formed by mixing an acceptable additive it means a solid particle composed from the primary particle, and contains the term ⁇ atorvastatin, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, and a pharmaceutically acceptable additive.
- "Granule to be” means atorvastatin, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, and a primary particle formed by mixing a pharmaceutically acceptable additive, or a solid particle composed of primary particles.
- particle size may be expressed as a particle size distribution such that D(X) is Y (where X and Y are positive numbers).
- D(X) is Y
- the particle size distribution of a drug obtained by measuring the particle diameter of a drug in a formulation is represented by a cumulative curve, the particle size accumulates in the order of smallest X% (% is based on number, volume or weight) Is calculated) means that the particle diameter at point Y is Y.
- D(10) is the particle diameter of the point at which the particle size of the drug is 10% by accumulating the particle size in small order
- D(50) is the particle at the point of 50% by accumulating the particle size of the drug in small order.
- the diameter of, D (90) may be to represent the diameter of the particle at a point that is 90% by accumulating the particle size of the drug in small order.
- D(X) is alternatively expressed as D(0.X), and D(X) and D(0.X) can be used interchangeably.
- D(50) is also represented as D(0.5)
- D(10) and D(90) are also represented as D(0.1) and D(0.9), respectively.
- the particle size distribution D(X) represents the percentage of the total cumulative particles based on number, volume, or weight depends on the method used to measure the particle size distribution. Methods for measuring the particle size distribution and the type of% in this regard are known to those skilled in the art. For example, when the particle size distribution is measured by a well-known laser diffraction method, the X value in D(X) may represent the percentage calculated by the volume average. It is known to those skilled in the art that the results of particle size distribution measurements obtained by a particular method may correlate with those obtained from other techniques based on experience with conventional experiments. For example, laser diffraction provides a volume average particle size in response to the volume of the particle, which corresponds to a weight average particle size when the density is constant.
- the granules of the second layer may have a particle size distribution in which D 50 is 80 ⁇ m or more, but is not limited thereto, specifically, 80 ⁇ m to 260 ⁇ m, 90 ⁇ m to 240 ⁇ m, or It may be 100 ⁇ m to 235 ⁇ m.
- the granules of the second layer may provide easy tabletting properties during the tableting process with fimasartan and a two-layer tablet. In addition, it is possible to maintain excellent content uniformity of each component included in each tablet, it is possible to economically easily mass production.
- the granules of the second layer D 10 may be 14 to 70 ⁇ m, but is not limited thereto, specifically, the granules of the second layer may be 14 to 50 ⁇ m.
- the granules of the second layer may provide easy tabletting properties during the tableting process with fimasartan and a two-layer tablet.
- the granules of the second layer may be D 90 is 290 to 600 ⁇ m, but is not limited thereto, specifically, the granules of the second layer have D 90 of 300 to 550 ⁇ m or It may be 300 to 500 ⁇ m.
- the granules of the second layer may provide easy tabletting properties during the tableting process with fimasartan and a two-layer tablet. In addition, it is possible to maintain excellent content uniformity of each component included in each tablet, it is possible to economically easily mass production.
- the tablet may be a bilayer tablet form included in the first layer containing the fimasartan granules and the second layer containing the atorvastatin granules, but is not limited thereto.
- the term "tablet” means to include compressed pharmaceutical dosage forms of all shapes and sizes, and the term “bilayer tablet” does not mix two or more other components, and separates the compartments. Refers to a combination of two or more different components, each component independently present.
- the first layer of the bilayer tablet contains fimasartan granules
- the second layer may contain atorvastatin granules
- the fimasartan granules and atorvastatin granules independently present in the first and second layers Since they are not mixed with each other and exist independently in different compartments, treatment of cardiovascular diseases including hypertension can be more effectively performed.
- the term “fimasartan granules” refers to granules containing fimasartan, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof and a pharmaceutically acceptable additive
- the term “Atorvastatin granule” means a granule containing atorvastatin, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, and a pharmaceutically acceptable additive.
- first, second is used only to distinguish the various layers, films, steps, etc. from each other, and does not indicate order or to indicate importance, and the first and second
- the terms such as layer, film, step, etc. are not limited by the terms. Therefore, the terms such as first and second may not all be used identically in the detailed description, examples, and claims of the invention, and it is sufficient if each can be distinguished from each other by terms such as first and second. .
- the fimasartan, its pharmaceutically acceptable salt, its hydrate or solvate may be included in an amount of 0.5 to 240.0 mg per unit dosage form, but is not limited thereto. It may be included in an amount of 10 to 180 mg or 20 to 120 mg.
- the atorvastatin, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof may be included in an amount of 1.0 to 100.0 mg per unit dosage form, but is not limited thereto. May be included in an amount of 10 to 80 mg.
- the additives of the first layer and the second layer may be any one selected from the group consisting of excipients, dissolution aids, disintegrating agents, binders, lubricants, and mixtures thereof. no.
- the term "excipient” means any substance that is not a therapeutic agent, and is used as a carrier or medium for delivery of the therapeutic agent or is added to a pharmaceutical composition. This will improve handling and storage properties or allow and promote the formation of unit doses of the composition.
- the excipient may be any one or more selected from the group comprising precipitated calcium carbonate, lactose or hydrates thereof, microcrystalline cellulose, mannitol and colloidal silicon dioxide, and more specifically, precipitated calcium carbonate, microcrystalline cellulose, and lactose It may be any one or more selected from the group, but is not limited thereto.
- dissolution aid means a substance added for the purpose of increasing the solubility of a poorly soluble drug and easily dissolving in a solvent (mainly water).
- dissolution aids are isotonic solutions comprising physiological saline, glucose and other adjuvants such as D-sorbitol, D-mannose, D-mannitol and sodium chloride; Alcohol such as ethanol; Polyols such as propylene glycol and polyethylene glycol; And nonionic surfactants such as polysorbate 80 and HCO-50, but is not limited thereto.
- disintegrant means a substance added for the purpose of promoting disintegration of tablets, capsules, granules, etc. in the digestive fluid.
- disintegrants include crospovidone (crosslinked polyvinylpyrrolidone), croscarmellose sodium (crosslinked carboxymethylcellulose sodium), sodium starch glycolate, corn starch, pregelatinized starch, and low substituted It may be selected from the group consisting of hydroxypropyl cellulose and microcrystalline cellulose, but is not limited thereto.
- binder means a substance that is added to form a pill when making a pill or pill.
- binders include polyvinylpyrrolidone (povidone), copolymers of vinylpyrrolidone and other vinyl derivatives (copovidone), hydroxypropylmethylcellulose, methylcellulose, hydroxypropylcellulose and pregelatinized starch. It may be selected from the group consisting, but is not limited thereto.
- the term "lubricant” means an additive used to give fluidity to granules and make it easier for tablets to escape from the mold when making tablets.
- the lubricant may be talc, magnesium stearate, sodium stearyl fumarate, or colloidal silicon dioxide, but is not limited thereto.
- the granules of the second layer include a mixture of lactose hydrate and microcrystalline cellulose, and the mixture may include 40 to 50% by weight relative to the total weight of the granules of the second layer, It is not limited to this.
- the mixture of lactose hydrate and microcrystalline cellulose may affect the tableting process of atorvastatin granules in the tableting process when preparing a complex comprising an active ingredient of atorvastatin and fimasartan.
- the granules of the second layer may further include precipitated calcium carbonate, but are not limited thereto. Specifically, a large amount of precipitated calcium carbonate may be added for stabilization of atorvastatin in the purification process when preparing a combination of atorvastatin and fimasartan.
- the mixture of the lactose hydrate and microcrystalline cellulose may exhibit a particle size distribution in which D 50 is 75 ⁇ m or more, but is not limited thereto, and specifically, 75 ⁇ m to 200 ⁇ m, 85 ⁇ m to 180 It may be ⁇ m or 95 ⁇ m to 170 ⁇ m.
- D 50 is 75 ⁇ m or more, but is not limited thereto, and specifically, 75 ⁇ m to 200 ⁇ m, 85 ⁇ m to 180 It may be ⁇ m or 95 ⁇ m to 170 ⁇ m.
- the mixture of lactose hydrate and microcrystalline cellulose may exhibit a particle size distribution in which D 10 is 15 to 50 ⁇ m, but is not limited thereto, and specifically, 20 to 40 ⁇ m or 23 to 35 May be ⁇ m.
- D 10 is 15 to 50 ⁇ m, but is not limited thereto, and specifically, 20 to 40 ⁇ m or 23 to 35 May be ⁇ m.
- the mixture of lactose hydrate and microcrystalline cellulose may exhibit a particle size distribution in which D 90 is 150 to 400 ⁇ m, but is not limited thereto, specifically, 180 to 350 ⁇ m or 200 to 300 May be ⁇ m.
- D 90 is 150 to 400 ⁇ m
- the particle size of the granules of the second layer can be increased, thereby facilitating easy tabletting in the purification process when preparing a composite agent with fimasartan.
- the granules of the second layer, atorvastatin, a pharmaceutically acceptable salt thereof, hydrate or solvate thereof 1 to 10 parts by weight, excipients 50 to 99.9 parts by weight, dissolution aid 0.1 to 2 Parts by weight, 0.5 to 15 parts by weight of a disintegrant, 0.1 to 10 parts by weight of a binder, and 0.1 to 5 parts by weight of a lubricant, but is not limited thereto.
- the unit "parts by weight” may mean a ratio of weights between components, unless otherwise specified.
- the granules of the second layer include atorvastatin, a pharmaceutically acceptable salt thereof, 1 to 10 parts by weight of a hydrate or solvate, 50 to 99.9 parts by weight of an excipient, 0.1 to 2 parts by weight of a dissolution aid, and a disintegrant 0.5 to 15 parts by weight, 0.1 to 10 parts by weight of the binder and 0.1 to 5 parts by weight of the lubricant means that the granule of the second layer is atorvastatin, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, an excipient, a dissolution aid,
- the disintegrating agent, the binder and the lubricant may be mixed in a weight ratio of 1 to 10: 50 to 99.9: 0.1 to 2: 0.5 to 15: 0.1 to 10: 0.1 to 5 to form granules of the second layer.
- the granule of the second layer contains atorvastatin, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, an excipient, a solubilizer, a disintegrant, a binder, and a lubricant 3-7: 70-85: 0.1-0.5: 1 to 10: 0.5 to 2: may be mixed in a weight ratio of 0.1 to 0.5 to form the atorvastatin granule portion.
- the granule of the second layer is 1 to 20% by weight of atorvastatin, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, 50 to 98.2% by weight of an excipient, 0.1 to 5% by weight of a dissolution aid, 0.5 It may mean that the granules of the second layer are formed by mixing from 15 to 15% by weight of disintegrant, 0.1 to 10% by weight of binder, and 0.1 to 5% by weight of lubricant.
- the granule of the second layer is 5 to 15% by weight of atorvastatin, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, 70 to 85% by weight of an excipient, 0.1 to 1% by weight of a dissolution aid, 1 to 10% by weight of disintegrant, 0.5 to 5% by weight of the binder and 0.1 to 3% by weight of the lubricant may be mixed means that the granules of the second layer was formed.
- the excipient may be any one of precipitated calcium carbonate, lactose hydrate, microcrystalline cellulose, or a mixture thereof, but is not limited thereto.
- the mixture of excipients may include 30 to 50 parts by weight of precipitated calcium carbonate, 20 to 40 parts by weight of lactose hydrate, and 15 to 35 parts by weight of microcrystalline cellulose, but is not limited thereto.
- the mixture may mean that a mixture of excipients is formed by mixing precipitated calcium carbonate, lactose hydrate, and microcrystalline cellulose in a weight ratio of 30 to 50: 20 to 40: 15 to 35.
- the tablet may be for the treatment of cardiovascular disease.
- cardiovascular disease means any disease that appears in the heart and/or vascular system (all blood vessels such as arteries, capillaries, and veins).
- the cardiovascular disease is hypertension, diabetes, obesity, hyperlipidemia, coronary artery disease, chronic stability angina, vasospastic angina, stroke, myocardial infarction, transient ischemic attack, congestive heart failure, insulin resistance, Impaired glucose tolerance, pre-diabetes, type 2 diabetes mellitus, diabetic nephropathy, dyslipidemia, cognitive dysfunction, dementia, and combinations thereof, but is not limited thereto.
- the tablet may be in the form of a coated tablet further comprising a coating layer on the outside, but is not limited thereto.
- Opadry Colorcon; 415 Moyer Blvd., P.O.Box 4, West Point, PA 19486-0024, U.S.A.
- the coating layer may be used as the coating layer.
- the tablet further comprising a coating layer on the outside may further include a light-emitting agent on the outside, but is not limited thereto.
- the term "lighting agent” means a substance that is polished on the surface of the formulation to improve the properties of the formulation.
- the brightener may be beeswax or carnauba wax, but is not limited thereto.
- the granules of the first layer and the second layer may be dry granules or wet granules, specifically wet granules.
- the present invention (S1) preparing a first layer containing granules containing fimasartan, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof and a pharmaceutically acceptable additive; (S2) preparing a second layer containing granules comprising atorvastatin, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, and a pharmaceutically acceptable additive; And (S3) tableting the first layer and the second layer to produce a two-layer tablet.
- the step of tableting the first layer and the second layer may be performed by applying a tableting pressure of 5 to 15 KN, but is not limited thereto.
- composition comprising tablets
- the present invention provides a pharmaceutical composition comprising the tablet.
- the pharmaceutical composition of the present invention shows a remarkable effect on the prevention and treatment of cardiovascular diseases.
- the pharmaceutical composition of the present invention may be for oral administration.
- oral administration means that the active substance is administered to a substance prepared to be digested, that is, to the gastrointestinal tract for absorption.
- Non-limiting examples of the formulation for oral administration include tablets, troches, lozenges, aqueous suspensions, oily suspensions, preparation powders, granules, emulsions, hard capsules, soft capsules, syrups or elixirs, etc. Can be heard.
- a binder such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose or gelatin, etc.
- Excipients such as dicalcium phosphate
- Disintegrants such as corn starch or sweet potato starch
- Lubricants such as magnesium stearate, calcium stearate, sodium stearyl fumarate, or polyethylene glycol wax can be used, and sweeteners, fragrances, syrups and the like can also be used.
- a liquid carrier such as fatty oil, etc. may be additionally used.
- the present invention provides a method of preventing or treating cardiovascular disease, comprising administering to a mammal, including a human, in a therapeutically effective amount of the tablet.
- prevention means a delay in the development of a disease, disorder or disease. Prevention may be considered complete if the onset of the disease, disorder or condition is delayed for a predetermined period of time.
- treatment partially or completely alleviates, ameliorates, alleviates, inhibits or delays the onset of a specific disease, disorder and/or disease, reduces the severity, or develops one or more symptoms or characteristics It means reducing.
- the term "therapeutically effective amount” is an effective amount of the tablet of the present invention effective for the prevention or treatment of cardiovascular disease, preventing the occurrence or recurrence of cardiovascular disease, alleviating symptoms, It may include all amounts of tablets that inhibit direct or indirect pathological consequences, prevent metastasis, reduce the rate of progression, alleviate or temporarily relieve the condition, or improve the prognosis. That is, the therapeutically effective amount may be interpreted to encompass all doses in which symptoms of cardiovascular disease are improved or cured by the tablet.
- the cardiovascular disease includes all of hypertension and complications of those with so-called metabolic syndrome, such as hypertension, or diabetes, obesity, hyperlipidemia, coronary artery disease, etc., and chronic stable angina. , Vasospastic angina, stroke, myocardial infarction, transient ischemic attack, congestive heart failure, insulin resistance, impaired glucose tolerance, type 2 diabetes mellitus, diabetic nephropathy, dyslipidemia, cognitive decline and dementia.
- the prophylactic or therapeutic methods of the present invention include not only treating the disease itself prior to the onset of symptoms by administering tablets, but also inhibiting or avoiding the symptoms thereof.
- the prophylactic or therapeutic dose of a particular active ingredient will vary depending on the nature and severity of the disease or condition and the route the active ingredient is administered. The dose and frequency of dose will vary depending on the age, weight and response of the individual patient. Suitable dosage regimens can be readily selected by those of ordinary skill in the art taking these factors into account.
- the treatment method of the present invention may further include the administration of a therapeutically effective amount of an additional active agent conducive to the treatment of a disease together with a tablet, and the additional active agent is synergistic or additive effect with the pharmaceutical composition. Can represent.
- mammals refers to each animal belonging to the mammalian class in the bio taxonomy.
- mammals including humans include mammals such as humans, monkeys, cows, horses, dogs, cats, rabbits, rats, and mice.
- the present invention provides the use of such tablets for use in the manufacture of cardiovascular disease agents.
- Tablets of the present invention for the manufacture of a pharmaceutical agent may mix the above-mentioned acceptable additives, etc., for example, within a range that does not impair the effects of the present invention, a pharmaceutically acceptable stabilizer, binder, disintegrant, lubricant Agents, diluents, coating agents, pH adjusting agents, dissolution aids, surfactants, and other additives may be included.
- the cardiovascular disease includes all of hypertension and complications of those with so-called metabolic syndrome, such as hypertension, or diabetes, obesity, hyperlipidemia, coronary artery disease, etc., and chronic stable angina. , Vasospastic angina, stroke, myocardial infarction, transient ischemic attack, congestive heart failure, insulin resistance, impaired glucose tolerance, type 2 diabetes mellitus, diabetic nephropathy, dyslipidemia, cognitive decline and dementia.
- the present invention provides the use of such tablets for the treatment of cardiovascular diseases.
- the cardiovascular disease includes all of hypertension and complications of those with so-called metabolic syndrome, such as hypertension, or diabetes, obesity, hyperlipidemia, coronary artery disease, etc., and chronic stable angina. , Vasospastic angina, stroke, myocardial infarction, transient ischemic attack, congestive heart failure, insulin resistance, impaired glucose tolerance, type 2 diabetes mellitus, diabetic nephropathy, dyslipidemia, cognitive decline and dementia.
- the present invention relates to a tablet and a method for manufacturing the same, and by adjusting the particle size distribution of the atorvastatin granules to a certain value or more, the tableting process is remarkably improved in the purification process with fimasartan, and thus it can exhibit excellent content uniformity, making it economically easy Mass production may be possible.
- FIG. 1 is a flow chart schematically showing a method for manufacturing a tablet of the present invention.
- Figure 2 shows the surface of the tablet according to Comparative Example 1.
- Figure 3 shows the surface of the tablet according to Example 1.
- Figure 4 shows the surface of the tablet according to Example 2.
- Example 5 shows the surface of a tablet according to Example 3.
- the fimasartan calcium trihydrate used in the following preparation example is Boryeong Pharmaceutical Co., Ltd.
- atorvastatin calcium trihydrate is Dr. reddy's
- precipitated calcium carbonate is Bihoku
- lactose hydrate is DFE Pharma
- microcrystalline cellulose is Asahi kasei
- poly Sorbate 80 is Croda
- croscarmellose sodium is DPE Pharma
- hydroxypropyl cellulose is Nippon soda
- magnesium stearate is FACI
- Opadry is Colorcon
- other reagents are purchased from sigma-aldrich.
- the granule part containing fimasartan potassium trihydrate as an active ingredient was prepared in the following manner so as to have the components and contents shown in Table 1 per unit dosage form (350 mg).
- fimasartan potassium trihydrate After mixing fimasartan potassium trihydrate, microcrystalline cellulose, and croscarmellose sodium for about 10 minutes, put the mixture in a high-speed stirrer and mix for about 3 minutes to prepare a mixture containing fimasartan as an active ingredient. Did.
- hydroxypropyl cellulose was dissolved in 41.7 mL of purified water to prepare a binding solution.
- the prepared binding solution was placed in a high-speed stirrer, wet granulated with a mixture containing the fimasartan as an active ingredient, and then dried by sizing with a 20 mesh sieve. After drying, croscarmellose sodium was added and mixed in a double cone mixer for about 5 minutes, magnesium stearate was added thereto and further mixed for about 5 minutes to prepare granules of fimasartan.
- Atorvastatin granules were prepared to have the content shown in Table 2 per unit dosage form (350 mg).
- Atorvastatin calcium trihydrate (D 50 : 3 ⁇ m), precipitated calcium carbonate (D 50 : less than 45 ⁇ m), lactose hydrate (D 50 : 40 ⁇ m) microcrystalline cellulose (D 50 : 50 ⁇ m), polysorbate 80 about 10
- the mixture was put in a high-speed stirrer and mixed for about 3 minutes to prepare a mixture containing atorvastatin calcium trihydrate as an active ingredient.
- the particle size distribution of the mixture of lactose hydrate and microcrystalline cellulose was 12.33 ⁇ m for D 10 , 53.56 ⁇ m for D 50 , and 128.86 ⁇ m for D 90 .
- hydroxypropyl cellulose was dissolved in 60 mL of purified water to prepare a binding solution.
- magnesium stearate was added thereto and further mixed for about 5 minutes to prepare an atorvastatin granule part.
- Atorvastatin granules were prepared to have the content shown in Table 3 per unit dosage form (350 mg).
- Atorvastatin calcium trihydrate (D 50 : 3 ⁇ m), precipitated calcium carbonate (D 50 : less than 45 ⁇ m), lactose hydrate (D 50 : 150 ⁇ m) microcrystalline cellulose (D 50 : 50 ⁇ m), polysorbate 80 about 10
- the mixture was put in a high-speed stirrer and mixed for about 3 minutes to prepare a mixture containing atorvastatin calcium trihydrate as an active ingredient.
- the particle size distribution of the mixture of lactose hydrate and microcrystalline cellulose that affects tableting of atorvastatin granules was 28.00 ⁇ m for D 10 , 97.70 ⁇ m for D 50 , and 229.38 ⁇ m for D 90 .
- hydroxypropyl cellulose was dissolved in 60 mL of purified water to prepare a binding solution.
- magnesium stearate was added thereto and further mixed for about 5 minutes to prepare an atorvastatin granule part.
- Atorvastatin granules were prepared to have the content shown in Table 4 per unit dosage form (350 mg).
- Atorvastatin calcium trihydrate (D 50 : 3 ⁇ m), precipitated calcium carbonate (D 50 : less than 45 ⁇ m), lactose hydrate (D 50 : 150 ⁇ m) microcrystalline cellulose (D 50 : 90 ⁇ m), polysorbate 80 about 10
- the mixture was put in a high-speed stirrer and mixed for about 3 minutes to prepare a mixture containing atorvastatin calcium trihydrate as an active ingredient.
- the particle size distribution of the mixture of lactose hydrate and microcrystalline cellulose that affects tableting of atorvastatin granules was 25.88 ⁇ m for D 10 , 115.11 ⁇ m for D 50 , and 234.22 ⁇ m for D 90 .
- hydroxypropyl cellulose was dissolved in 60 mL of purified water to prepare a binding solution.
- the particle size distribution of the granules containing atorvastatin calcium trihydrate as an active ingredient was 24.59 ⁇ m in D 10 , 160.02 ⁇ m in D 50 , and 494.80 ⁇ m in D 90 .
- magnesium stearate was added thereto and further mixed for about 5 minutes to prepare an atorvastatin granule part.
- Atorvastatin granules were prepared to have the content shown in Table 5 per unit dosage form (350 mg).
- Atorvastatin calcium trihydrate (D 50 : 3 ⁇ m), precipitated calcium carbonate (D 50 : less than 45 ⁇ m), lactose hydrate (D 50 : 150 ⁇ m) microcrystalline cellulose (D 50 : 170 ⁇ m), polysorbate 80 about 10
- the mixture was put in a high-speed stirrer and mixed for about 3 minutes to prepare a mixture containing atorvastatin calcium trihydrate as an active ingredient.
- the particle size distribution of the mixture of lactose hydrate and microcrystalline cellulose that affects tableting of atorvastatin granules was 52.99 ⁇ m for D 10 , 115.11 ⁇ m for D 50 , and 282.48 ⁇ m for D 90 .
- hydroxypropyl cellulose was dissolved in 60 mL of purified water to prepare a binding solution.
- magnesium stearate was added thereto and further mixed for about 5 minutes to prepare an atorvastatin granule part.
- Atorvastatin granules were prepared to have the content shown in Table 2 per unit dosage form (350 mg).
- Atorvastatin calcium trihydrate (D 50 : 3 ⁇ m), precipitated calcium carbonate (D 50 : less than 45 ⁇ m), lactose hydrate (D 50 : 40 ⁇ m) microcrystalline cellulose (D 50 : 50 ⁇ m), polysorbate 80 about 10
- the mixture was put in a high-speed stirrer and mixed for about 3 minutes to prepare a mixture containing atorvastatin calcium trihydrate as an active ingredient.
- the particle size distribution of the mixture of lactose hydrate and microcrystalline cellulose was 12.33 ⁇ m for D 10 , 53.56 ⁇ m for D 50 , and 128.86 ⁇ m for D 90 .
- hydroxypropyl cellulose was dissolved in 70 mL of purified water to prepare a binding solution.
- croscarmellose sodium was added and mixed in a double cone mixer for about 5 minutes, magnesium stearate was added thereto, and further mixed for about 5 minutes to prepare atorvastatin granules.
- Atorvastatin granules were prepared to have the content shown in Table 2 per unit dosage form (350 mg).
- Atorvastatin calcium trihydrate (D 50 : 3 ⁇ m), precipitated calcium carbonate (D 50 : less than 45 ⁇ m), lactose hydrate (D 50 : 40 ⁇ m) microcrystalline cellulose (D 50 : 50 ⁇ m), polysorbate 80 about 10
- the mixture was put in a high-speed stirrer and mixed for about 3 minutes to prepare a mixture containing atorvastatin calcium trihydrate as an active ingredient.
- the particle size distribution of the mixture of lactose hydrate and microcrystalline cellulose was 12.33 ⁇ m for D 10 , 53.56 ⁇ m for D 50 , and 128.86 ⁇ m for D 90 .
- hydroxypropyl cellulose was dissolved in 60 mL of purified water to prepare a binding solution.
- magnesium stearate was added thereto and further mixed for about 5 minutes to prepare an atorvastatin granule part.
- the granules containing fimasartan potassium trihydrate according to ⁇ Preparation Example 1> as an active ingredient and the granules containing atorvastatin calcium trihydrate according to ⁇ Preparation 2-2> as an active ingredient are respectively placed in a punch die and 5-15 KN.
- the tablet was compressed into tablets to prepare a two-layer tablet.
- the hardness of the double-layered tablet was prepared using a multi-layer tableting tablet (Pichola two-layered tableting tablet) so that the hardness was 5 to 20 kp.
- a coating tablet was prepared using 10.5 mg of Opadry (Colorcon; 415 Moyer Blvd., PO Box 4, West Point, PA 19486-0024, USA,), and 0.5 mg of carnauba wax was used on the surface of the coating tablet. It was polished to prepare a bilayer tablet comprising fimasartan and atorvastatin.
- the granules containing fimasartan potassium trihydrate according to ⁇ Preparation Example 1> as an active ingredient and the granules containing atorvastatin calcium trihydrate according to ⁇ Preparation 2-3> as an active ingredient are respectively placed in a punch die and 5-15 KN.
- the tablet was compressed into tablets to prepare a two-layer tablet.
- the hardness of the double-layered tablet was prepared using a multi-layer tableting tablet (Pichola two-layered tableting tablet) so that the hardness was 5 to 20 kp.
- a coating tablet was prepared using 10.5 mg of Opadry (Colorcon; 415 Moyer Blvd., PO Box 4, West Point, PA 19486-0024, USA,), and 0.5 mg of carnauba wax was used on the surface of the coating tablet. It was polished to prepare a bilayer tablet comprising fimasartan and atorvastatin.
- Granules containing fimasartan potassium trihydrate according to ⁇ Production Example 1> as an active ingredient and granules containing atorvastatin calcium trihydrate according to ⁇ Production Example 2-4> as an active ingredient were respectively placed in a punch die and 5-15 KN. The tablet was compressed into tablets to prepare a two-layer tablet.
- the hardness of the double-layered tablet was prepared using a multi-layer tableting tablet (Pichola two-layered tableting tablet) so that the hardness was 5 to 20 kp.
- a coating tablet was prepared using 10.5 mg of Opadry (Colorcon; 415 Moyer Blvd., PO Box 4, West Point, PA 19486-0024, USA,), and 0.5 mg of carnauba wax was used on the surface of the coating tablet. It was polished to prepare a bilayer tablet comprising fimasartan and atorvastatin.
- Bilayer tablet comprising fimasartan and atorvastatin
- the granules containing fimasartan potassium trihydrate according to ⁇ Production Example 1> as an active ingredient and the granules containing atorvastatin calcium trihydrate according to ⁇ Production Example 2-5> as an active ingredient are respectively placed in a punch die and 5-15 KN.
- the tablet was compressed into tablets to prepare a two-layer tablet.
- the hardness of the double-layered tablet was prepared using a multi-layer tableting tablet (Pichola two-layered tableting tablet) so that the hardness was 5 to 20 kp.
- a coating tablet was prepared using 10.5 mg of Opadry (Colorcon; 415 Moyer Blvd., PO Box 4, West Point, PA 19486-0024, USA,), and 0.5 mg of carnauba wax was used on the surface of the coating tablet. It was polished to prepare a bilayer tablet comprising fimasartan and atorvastatin.
- Bilayer tablet comprising fimasartan and atorvastatin
- the granules containing fimasartan potassium trihydrate according to ⁇ Production Example 1> as an active ingredient and the granules containing atorvastatin calcium trihydrate according to ⁇ Production Example 2-6> as an active ingredient were respectively placed in a punch die and 5-15 KN.
- the tablet was compressed into tablets to prepare a two-layer tablet.
- the hardness of the double-layered tablet was prepared using a multi-layer tableting tablet (Pichola two-layered tableting tablet) so that the hardness was 5 to 20 kp.
- a coating tablet was prepared using 10.5 mg of Opadry (Colorcon; 415 Moyer Blvd., PO Box 4, West Point, PA 19486-0024, USA,), and 0.5 mg of carnauba wax was used on the surface of the coating tablet. It was polished to prepare a bilayer tablet comprising fimasartan and atorvastatin.
- Granules containing fimasartan potassium trihydrate according to ⁇ Production Example 1> as an active ingredient and granules containing atorvastatin calcium trihydrate according to ⁇ Production Example 2-1> as an active ingredient were respectively placed in a punch die and 5-15 KN. The tablet was compressed into tablets to prepare a two-layer tablet.
- the hardness of the double-layered tablet was prepared using a multi-layer tableting tablet (Pichola two-layered tableting tablet) so that the hardness was 5 to 20 kp.
- a coating tablet was prepared using 10.5 mg of Opadry (Colorcon; 415 Moyer Blvd., PO Box 4, West Point, PA 19486-0024, USA,), and 0.5 mg of carnauba wax was used on the surface of the coating tablet. It was polished to prepare a bilayer tablet comprising fimasartan and atorvastatin.
- the particle size of the granules containing the obtained atorvastatin calcium trihydrate as an active ingredient and the mixture of lactose hydrate and microcrystalline cellulose that affects tableting of the atorvastatin granules was measured using a HELOS particle size analyzer (Laser particle size analyzer) of Sumpatec by a dry method.
- Examples 1 to 3 are tablets each containing granules containing atorvastatin calcium trihydrate as an active ingredient according to ⁇ Production Examples 2-2> to ⁇ Production Examples 2-4> to prepare bilayer tablets, wherein the granules are D 50 will have a particle size distribution of 80.00 ⁇ m or more.
- the particle size distribution of the granules is below a certain level, it was confirmed that the tableting process causes sticking disorders such as sticking, and it was confirmed that the tablet properties (engraving, etc.) do not meet the drug standards.
- the particle size distribution of lactose hydrate and microcrystalline cellulose mixture (D 50 ) To adjust the particle size distribution (D 50 ) of granules containing atorvastatin calcium trihydrate as an active ingredient to a certain level or more, resulting in a tableting disorder when performing the tableting process in the process of tabletting fimasartan and atorvastatin into two-layer tablets It was confirmed not to be.
- the amount of the binding liquid is increased during wet granulation according to ⁇ Production Example 2-5>, or the size of the formulation is adjusted according to ⁇ Production Example 2-6>. If increased, it is possible to obtain the ⁇ Preparation example 2-1> atorvastatin calcium distribution (D 50) particle size of the granules than the increased distribution (D 50) particle size of the granules containing the trihydrate as the active ingredient in accordance with, and as a result Pima It was confirmed that the tableting process, such as sticking, did not occur when the tableting process was performed in the process of tableting with salt.
- granules containing atorvastatin calcium trihydrate according to ⁇ Preparation Example 2-1> as an active ingredient have tableting disorders such as sticking during tableting, resulting in target weight (200 mg). Even if the equipment conditions were set properly, the target weight was not reached, and the mass deviation of the tablets was largely found to be judged to be unsuitable for the content uniformity (judgment value: 15.4, judgment factor: 2.4, reference value: 98.5).
- a large amount of precipitated calcium carbonate should be added as a stabilizer, which is fine, so tableting disorders such as sticking during tableting of atorvastatin granules It will cause it to happen.
- the particle size distribution (D 50 ) of granules containing atorvastatin calcium trihydrate as an active ingredient is adjusted to a particle size (D 50 ) for a mixture of lactose hydrate and microcrystalline cellulose, thereby providing tabletting stability. It was confirmed that this can be markedly improved and exhibit excellent content uniformity.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Description
Claims (23)
- 피마살탄, 이의 약학적으로 허용 가능한 염, 이의 수화물 또는 용매화물과 약제학적으로 허용 가능한 첨가제를 함유하는 피마살탄 과립부; 및아토르바스타틴, 이의 약학적으로 허용 가능한 염, 이의 수화물 또는 용매화물과 약제학적으로 허용 가능한 첨가제를 함유하는 아토르바스타틴 과립부를 포함하고,상기 피마살탄 과립부와 아토르바스타틴 과립부는 각각 분리된 상태로 존재하는 것인 정제.
- 피마살탄, 이의 약학적으로 허용 가능한 염, 이의 수화물 또는 용매화물과 약제학적으로 허용 가능한 첨가제를 함유하는 과립을 포함하는 제1층; 및아토르바스타틴, 이의 약학적으로 허용 가능한 염, 이의 수화물 또는 용매화물과 약제학적으로 허용 가능한 첨가제를 함유하는 과립을 포함하는 제2층을 포함하고,상기 제2층의 과립은 D 50이 80 ㎛ 이상인 입도분포를 나타내는 것인 정제.
- 제2항에 있어서, 상기 제2층의 과립은 D 10이 14 내지 70 ㎛ 인 입도분포를 나타내는 것인 정제.
- 제2항에 있어서, 상기 제2층의 과립은 D 90이 290 내지 600 ㎛ 인 입도분포를 나타내는 것인 정제.
- 제2항에 있어서, 상기 정제는 이층정인 것인 정제.
- 제2항에 있어서, 상기 피마살탄, 이의 약학적으로 허용 가능한 염, 이의 수화물 또는 용매화물이 단위 제형 당 0.5 내지 240.0 mg의 양으로 포함되는 것인 정제.
- 제2항에 있어서, 상기 아토르바스타틴, 이의 약학적으로 허용 가능한 염, 이의 수화물 또는 용매화물이 단위 제형 당 1.0 내지 100.0 mg의 양으로 포함되는 것인 정제.
- 제2항에 있어서, 상기 제1층 및 제2층의 첨가제는 부형제, 용해보조제, 붕해제, 결합제, 활택제 및 이의 혼합물로 이루어진 군에서 선택된 어느 하나인 것인 정제.
- 제2항에 있어서, 상기 제2층의 과립은,유당 수화물과 미결정 셀룰로오스의 혼합물을 포함하며, 상기 혼합물은 제2층의 과립 전체 중량에 대해 40 내지 50 중량%를 포함하는 것인 정제.
- 제9항에 있어서, 상기 제2층의 과립은,침강탄산칼슘을 더 포함하는 것인 정제.
- 제9항에 있어서, 상기 유당 수화물과 미결정 셀룰로오스의 혼합물은,D 50이 75 ㎛ 이상의 입도분포를 나타내는 것인 정제.
- 제2항에 있어서, 상기 제2층의 과립은,아토르바스타틴, 이의 약학적으로 허용 가능한 염, 이의 수화물 또는 용매화물 1 내지 10 중량부, 부형제 50 내지 99.9 중량부, 용해보조제 0.1 내지 2 중량부, 붕해제 0.5 내지 15 중량부, 결합제 0.1 내지 10 중량부 및 활택제 0.1 내지 5 중량부를 포함하는 정제.
- 제12항에 있어서, 상기 부형제는 침강탄산칼슘, 유당 수화물, 미결정 셀룰로오스, 또는 이들의 혼합물 중 어느 하나인 것인 정제.
- 제13항에 있어서, 상기 혼합물은 침강탄산칼슘 30 내지 50 중량부, 유당 수화물 20 내지 40 중량부 및 미결정 셀룰로오스 15 내지 35 중량부를 포함하는 것인 정제.
- 제2항에 있어서, 상기 정제는 코팅층을 추가로 포함하는 정제.
- 제2항에 있어서, 상기 제1층 및 제2층의 과립은 습식과립인 것인 정제.
- (S1) 피마살탄, 이의 약학적으로 허용 가능한 염, 이의 수화물 또는 용매화물과 약제학적으로 허용 가능한 첨가제를 포함하는 과립을 함유하는 제1층을 제조하는 단계;(S2) 아토르바스타틴, 이의 약학적으로 허용 가능한 염, 이의 수화물 또는 용매화물과 약제학적으로 허용 가능한 첨가제를 포함하는 과립을 함유하는 제2층을 제조하는 단계; 및(S3) 상기 제1층 및 제2층을 타정하여 이층정을 제조하는 단계를 포함하는, 정제의 제조방법.
- 제17항에 있어서, 상기 상기 피마살탄 과립부 및 상기 아토르바스타틴 과립부를 타정하는 단계는,5 내지 15 KN의 타정압을 가하여 수행되는 것인 제조방법.
- 제2항에 있어서, 상기 정제는 심혈관계 질환 치료용인 정제.
- 제2항에 따른 정제를 치료학적으로 유효한 양으로 인간을 포함한 포유류에게 투여하는 단계를 포함하는 심혈관계 질환의 예방 또는 치료 방법.
- 심혈관계 질환의 예방 또는 치료용 제제의 제조에 사용하기 위한 제2항에 따른 정제의 용도.
- 심혈관계 질환의 예방 또는 치료를 위한, 제2항에 따른 정제의 용도.
- 제19항 내지 제22항 중 어느 한 항에 있어서, 상기 심혈관계 질환은 고혈압, 당뇨병, 비만증, 고지혈증, 관상 동맥 질환, 만성 안정성 협심증, 혈관경련성 협심증, 뇌졸중, 심근경색증, 일시적 허혈발작, 울혈성 심부전증, 인슐린 내성, 손상된 글루코스 내성, 예비당뇨병, 2형 진성 당뇨병, 당뇨성 신증, 이상지질혈증, 인지기능저하, 치매, 및 이들의 조합으로부터 선택되는 질환인 것인 정제.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020217024291A KR102465736B1 (ko) | 2018-12-31 | 2019-12-30 | 정제 및 이의 제조방법 |
CN201980087258.0A CN113260355A (zh) | 2018-12-31 | 2019-12-30 | 片剂及其制备方法 |
SG11202106025WA SG11202106025WA (en) | 2018-12-31 | 2019-12-30 | Tablet and method of preparing same |
MX2021007734A MX2021007734A (es) | 2018-12-31 | 2019-12-30 | Comprimido y metodo de preparacion del mismo. |
PH12021551334A PH12021551334A1 (en) | 2018-12-31 | 2021-06-07 | Tablet and method of preparing same |
ZA2021/04403A ZA202104403B (en) | 2018-12-31 | 2021-06-25 | Tablet and method of preparing same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0173649 | 2018-12-31 | ||
KR20180173649 | 2018-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020141825A1 true WO2020141825A1 (ko) | 2020-07-09 |
Family
ID=71407061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/018684 WO2020141825A1 (ko) | 2018-12-31 | 2019-12-30 | 정제 및 이의 제조방법 |
Country Status (7)
Country | Link |
---|---|
KR (1) | KR102465736B1 (ko) |
CN (1) | CN113260355A (ko) |
MX (1) | MX2021007734A (ko) |
PH (1) | PH12021551334A1 (ko) |
SG (1) | SG11202106025WA (ko) |
WO (1) | WO2020141825A1 (ko) |
ZA (1) | ZA202104403B (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022260439A1 (ko) * | 2021-06-09 | 2022-12-15 | 주식회사 보령 | 약학적 복합 제제 및 제조 방법 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110126020A (ko) * | 2010-05-14 | 2011-11-22 | 한미홀딩스 주식회사 | HMG-CoA 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제 |
KR20170061615A (ko) * | 2015-11-26 | 2017-06-05 | 보령제약 주식회사 | 피마살탄의 신규 염 |
EP3184103A1 (en) * | 2015-12-21 | 2017-06-28 | Hexal AG | Pharmaceutical composition comprising atorvastatin or a salt thereof |
-
2019
- 2019-12-30 CN CN201980087258.0A patent/CN113260355A/zh active Pending
- 2019-12-30 MX MX2021007734A patent/MX2021007734A/es unknown
- 2019-12-30 KR KR1020217024291A patent/KR102465736B1/ko active IP Right Grant
- 2019-12-30 WO PCT/KR2019/018684 patent/WO2020141825A1/ko active Application Filing
- 2019-12-30 SG SG11202106025WA patent/SG11202106025WA/en unknown
-
2021
- 2021-06-07 PH PH12021551334A patent/PH12021551334A1/en unknown
- 2021-06-25 ZA ZA2021/04403A patent/ZA202104403B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110126020A (ko) * | 2010-05-14 | 2011-11-22 | 한미홀딩스 주식회사 | HMG-CoA 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제 |
KR20170061615A (ko) * | 2015-11-26 | 2017-06-05 | 보령제약 주식회사 | 피마살탄의 신규 염 |
EP3184103A1 (en) * | 2015-12-21 | 2017-06-28 | Hexal AG | Pharmaceutical composition comprising atorvastatin or a salt thereof |
Non-Patent Citations (2)
Title |
---|
ANONYMOUS: "A clinical trial to evaluate the pharmacokinetics and safety/tolerability of fimasartan and atorvastatin in healthy male volunteers", CLINICAL TRIALS, 18 January 2018 (2018-01-18), pages 1 - 5, XP055722876, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT02994745> * |
CHOI, Y. ET AL.: "Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers", DRUG DESIGN, DEVELOPMENT AND THERAPY, vol. 12, 24 July 2018 (2018-07-24), pages 2301 - 2309, XP055722880 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022260439A1 (ko) * | 2021-06-09 | 2022-12-15 | 주식회사 보령 | 약학적 복합 제제 및 제조 방법 |
Also Published As
Publication number | Publication date |
---|---|
CN113260355A (zh) | 2021-08-13 |
KR102465736B1 (ko) | 2022-11-11 |
ZA202104403B (en) | 2023-01-25 |
MX2021007734A (es) | 2021-08-05 |
SG11202106025WA (en) | 2021-07-29 |
PH12021551334A1 (en) | 2021-12-06 |
KR20210100202A (ko) | 2021-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015102400A1 (en) | Composite formulation for oral administration comprising ezetimibe and rosuvastatin | |
WO2019221473A1 (ko) | Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물 | |
WO2017007287A1 (ko) | 암로디핀, 발사르탄 및 로수바스타틴을 포함하는 약학적 조성물 | |
WO2018111002A1 (ko) | 카바메이트 화합물을 포함하는 구강 붕해 정제 | |
WO2016159535A1 (en) | Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone | |
WO2019182276A1 (en) | Pharmaceutical combination preparation comprising ezetimibe and rosuvastatin | |
WO2020141825A1 (ko) | 정제 및 이의 제조방법 | |
WO2018080104A1 (ko) | 에스오메프라졸 함유 복합 캡슐제 및 그 제조방법 | |
WO2023068839A1 (ko) | 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 안정성이 개선된 필름코팅 정제 | |
WO2020130502A1 (ko) | 엠파글리플로진 및 시타글립틴을 포함하는 약학적 조성물 | |
WO2018199636A1 (en) | A combination formulation comprising hmg-coa reductase inhibitor and calcium channel blocker | |
WO2017073897A1 (en) | Pharmaceutical composition comprising metformin and lobeglitazone | |
WO2019221488A1 (en) | Pharmaceutical formulation comprising apixaban and method for preparing the same | |
WO2016052866A1 (en) | Solid pharmaceutical composition comprising amlodipine and losartan | |
WO2013157840A1 (ko) | 안정성이 향상된 암로디핀 및 로잘탄을 함유하는 복합제 조성물 | |
WO2018160011A1 (ko) | 피르페니돈의 입자크기 조절에 따른 타정성이 개선된 약제학적 조성물 및 이의 제조방법 | |
WO2021145676A1 (ko) | 아토르바스타틴 및 에제티미브를 포함하는 정제 | |
WO2017155350A1 (ko) | (±)-2-[2-(3-카르복시프로피오닐옥시)-3-디메틸아미노프로폭시]-3'-메톡시비벤질 또는 그의 염을 포함하는 경구용 약학 조성물 | |
WO2020204609A1 (ko) | 에스오메프라졸 또는 이의 약학적으로 허용 가능한 염을 포함하고 이중방출 프로파일을 갖는 약학적 조성물 | |
WO2013169082A1 (ko) | 보센탄 제어방출성 경구제제 | |
WO2022270935A1 (en) | Pharmaceutical combination preparation comprising candesartan, amlodipine and atorvastatin | |
WO2017048033A1 (en) | Pharmaceutical combination preparation | |
WO2013187700A1 (ko) | 메트포르민 및 HMG-CoA 환원효소 억제제를 포함하는 약제학적 복합제제 | |
WO2018044020A1 (ko) | 에페리손 서방성 미립구의 제조방법 및 에페리손 서방성 미립구와 아세클로페낙 복합제제 | |
WO2022010078A1 (ko) | 시타글립틴 및 다파글리플로진을 포함하는 복합제제 및 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19906655 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20217024291 Country of ref document: KR Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19906655 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 521422378 Country of ref document: SA |